ArticleCureus2026
Serious Adverse Events Following COVID-19 Vaccination: A Descriptive Case Series From a Rural Healthcare System.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim COVID-19 mRNA vaccines were granted Emergency Use Authorization by the United States FDA in December 2020. Serious adverse events following immunization (AEFI) with COVID-19 vaccines started to be seen by clinicians soon after the vaccines were available to the public. The objective of this study is to report the clinical course of patients with adverse events following COVID-19 vaccination encountered in medical practice. Methods These cases (age range, 18-82 years) were prospectively identified and collected by the authors during formal or informal consultation from January to December 2021. Cases were excluded from further consideration for AEFI with COVID-19 vaccines if an alternative explanation was deemed more likely at the time of consultation. The authors did not solicit medical providers, patients, or the public, nor screen medical records for adverse events following COVID-19 vaccination. This is a descriptive case series; therefore, no statistical analysis was performed. Results We encountered 18 patients with AEFI, nine (50%) males (range, 22-78 years) and nine (50%) females (range, 18-82 years). Clinical presentations involved various organ systems, including cardiovascular (five), nervous system (five), immune system/hematologic (four), skin (one), gastrointestinal (one), pulmonary (one), and infection (two). This paper details their clinical courses. Conclusions We encountered a variety of AEFI, including myocarditis, demyelinating disease, encephalitis, Bell's palsy, burning mouth syndrome, multisystem inflammatory syndrome, immune thrombocytopenia, pneumonitis, colitis, staphylococcal infection, and erythromelalgia. This detailed case series was presented to help clinicians consider a diagnosis of AEFI for patients when no other explanation has been found after a thorough diagnostic evaluation. These described adverse events following COVID-19 vaccination do not imply causality. We hope this descriptive case series leads to further case-control studies from healthcare organizations to explore the possible risks, incidence, and causal relationships of such adverse events following COVID-19 vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.